Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1247.2000 27.10 (2.22%)
NSE Apr 28, 2025 15:31 PM
Volume: 1.1M
 

1247.20
2.22%
ICICI Securities Limited
Aurobindo Pharma’s Q3FY25 performance was below our expectation due to lower-than-anticipated sales in US while Europe (up 22.7% YoY) and growth markets (up 39.2% YoY) maintained traction. EBITDA margin was 20.4% despite lower gRevlimid sales and INR 600mn cost of Pen-G plant.
Aurobindo Pharma Ltd. is trading above its 100 day SMA of 1183.2
More from Aurobindo Pharma Ltd.
Recommended